AGM Trading Update – Solid start to the year
18 November 2026
Genus plc (“Genus” or the “Group”)
AGM Trading Update – Solid start to the year
Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the four months ended 31 October 2026 to coincide with its AGM at 11:00am GMT today.
Genus has made a solid start to the year against a backdrop of softer global agricultural markets. Group FY27 adjusted profit before tax in constant currency is expected to be in line with current market expectations1 and second half weighted, as previously guided. Depreciation of the Brazilian real and Mexican peso against sterling during the period is now expected to result in a £3m to £4m adverse currency impact for the year, assuming current exchange rates persist.
PIC has delivered resilient trading despite challenging end-markets for its customers, reflecting the strength of its royalty-based business model, strong product performance and long-standing customer relationships.
ABS trading has been challenging as low global dairy prices continue to weigh on customer profitability. Management expects a material improvement in the second half supported by commercial and operational initiatives.
Genus will announce its interim results for the six months ending 31 December 2026 on 25 February 2027.
For further information please contact:
|
Genus plc |
Tel: +44 1256 345 970 |
|
Jorgen Kokke, Chief Executive Officer |
|
|
Andy Russell, Chief Financial Officer |
|
|
Anand Date, Investor Relations & Sustainability Director |
|
|
Tavistock Communications |
Tel: +44 2074 665 000 |
|
Nick Dibden |
|
|
Katie Hopkins |
|
|
Saskia Zilkha |
|
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS Resistant Pig is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Footnotes
1 The Company compiled consensus estimate range for Group FY27 actual currency adjusted profit before tax is £91.0m to £94.5m with an average midpoint of £93.3m, and is based upon 13 analyst estimates
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE